Equities

Chengdu Easton Biopharmaceuticals Co Ltd

  • Add to watchlist
  • Add to portfolio
  • Add an alert

Chengdu Easton Biopharmaceuticals Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (CNY)64.39
  • Today's Change-2.12 / -3.19%
  • Shares traded1.27m
  • 1 Year change+114.28%
  • Beta0.5664
Data delayed at least 15 minutes, as of Feb 13 2026.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Chengdu Easton Biopharmaceuticals Co Ltd is a China-based company mainly engaged in the research, development, production and sales of chemical raw materials and chemical pharmaceutical preparations. The Company's main products are generic chemical drugs, including nalmefene hydrochloride injection, ibuprofen injection, bisoprolol fumarate tablets and ubenimex. The products are used in anesthesia and analgesia, cardiovascular and cerebrovascular, anti-tumor and endocrine applications. The Company distributes its products in/within the domestic market and to overseas markets.

  • Revenue in CNY (TTM)1.33bn
  • Net income in CNY241.37m
  • Incorporated2009
  • Employees1.52k
  • Location
    Chengdu Easton Biopharmaceuticals Co LtdNo. 8 Ankang Road, Shuangliu DistrictCHENGDU 610219ChinaCHN
  • Phone+86 2 886106668
  • Fax+86 2 862321999
  • Websitehttp://www.eastonpharma.cn
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Liaoning Chengda Biotechnology Co Ltd1.47bn177.94m10.67bn1.81k59.191.14--7.260.4330.4333.5622.540.14820.67861.24813,192.101.798.071.868.3679.0384.9812.1135.7519.28--0.001344.77-4.22-0.0082-26.42-13.26-4.72--
Jiangsu Sinopep Allsin Bphrmctcl Co Ltd1.90bn498.69m10.68bn2.03k21.173.43--5.621.601.606.139.840.34130.93063.06936,748.908.907.1913.049.6766.6459.3026.0820.280.92816.070.460435.8957.2134.33148.1952.7631.58--
Aurisco Pharmaceutical Co Ltd1.62bn424.54m10.78bn1.78k25.084.24--6.631.061.064.076.260.41881.094.41910,578.1010.9411.3712.6013.2959.7752.9326.1322.343.01635.150.280631.5316.8920.4722.5913.7749.45--
Chengdu Olymvax Biopharmaceuticals Inc709.13m64.21m11.01bn470.00170.9411.47--15.520.15870.15871.752.360.38830.6541.191,508,792.003.453.255.004.8192.6693.628.888.111.428.300.29067.3918.6926.8818.24--48.00--
Shanghai Yizhong Pharmaceutical Co Ltd247.05m22.96m11.02bn65.00471.027.54--44.600.11320.11321.227.070.1630.95562.263,800,801.001.515.441.585.6481.3992.999.3036.907.84--0.0032.30-51.83---95.68--10.96--
Cansino Biologics Inc971.83m-142.03m11.23bn1.11k--2.99--11.55-0.5455-0.54553.9221.370.12710.58611.38879,482.50-1.86-4.08-2.29-5.3878.8045.31-14.62-27.513.29--0.2242--137.01226.4374.45--31.38--
Zhejiang CONBA Pharmaceutical Co., Ltd.6.58bn687.99m11.23bn8.26k16.621.58--1.710.26650.26652.542.800.66172.574.70796,529.007.138.519.6512.7451.8858.6410.7714.121.38--0.053241.54-3.23-0.75945.21--1.57--
Chengdu Easton Biopharmaceuticals Co Ltd1.33bn241.37m11.37bn1.52k46.913.97--8.551.371.377.5516.230.38091.835.89873,161.506.928.098.449.8271.9081.7218.1620.103.12--0.044430.3720.827.345.1517.014.24--
Mayinglong Pharmaceutical Group Co Ltd3.77bn571.60m11.66bn2.65k20.392.71--3.091.331.338.759.970.72116.2311.991,421,812.0011.3810.7713.8213.3546.7742.4015.7814.394.58--0.022637.3118.856.6219.147.9734.4718.98
Jiangxi Tianxin Pharmaceutical Co Ltd2.23bn617.04m11.82bn2.68k19.072.47--5.311.421.425.1110.930.39732.439.65830,883.1011.0117.1011.8821.1643.0442.9927.7230.124.31--0.072124.4117.351.7536.85-2.2035.06--
Data as of Feb 13 2026. Currency figures normalised to Chengdu Easton Biopharmaceuticals Co Ltd's reporting currency: Chinese Yuan Renminbi CNY

Institutional shareholders

10.44%Per cent of shares held by top holders
HolderShares% Held
Bosera Asset Management Co., Ltd.as of 30 Jun 20256.61m3.74%
China Universal Asset Management Co., Ltd.as of 30 Jun 20252.80m1.59%
Cathay Securities Investment Trust Co., Ltd.as of 31 Mar 20252.32m1.32%
China Fund Management Co., Ltd.as of 30 Jun 20252.15m1.22%
CCB Principal Asset Management Co., Ltd.as of 30 Jun 20251.13m0.64%
Guotai Asset Management Co., Ltd.as of 30 Jun 2025919.76k0.52%
CIB Fund Management Co., Ltd.as of 30 Jun 2025713.87k0.40%
ABC-CA Fund Management Co., Ltd.as of 30 Jun 2025634.85k0.36%
First Seafront Fund Management Co., Ltd.as of 30 Jun 2025580.35k0.33%
First-Trust Fund Management Co., Ltd.as of 30 Jun 2025557.13k0.32%
More ▼
Data from 30 Jun 2025 - 12 Feb 2026Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.